Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1993-12-17
1996-08-13
Chan, Christina Y.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
530402, 5303915, 5303911, 5303919, 530300, 530317, 530319, 530322, 530345, 530350, C07K 1600, C07K 1700
Patent
active
055457215
ABSTRACT:
Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Methods for treating acute infections with advantages over current therapeutic approaches are provided. Conjugates and methods of making conjugates for the prevention and treatment of sepsis are described.
REFERENCES:
patent: 4867973 (1989-09-01), Goers et al.
patent: 4918163 (1990-04-01), Young et al.
G. W. Machiedo et al., "Patterns of Mortality in a Surgical Intensive Care Unit," Surg. Gyn. & Ob., 152:757-759 (1981).
D. D. Morris et al., "Endotoxemia in Neonatal Calves Given Antiserum to a Mutant Escherichia coli(J-5)," Am. J. Vet. Res., 47:2554-2565 (1986).
A. M. Hoffman et al., "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," J. Vet. Int. Med., 6:89-95 (1992).
S. M. Wolff, "Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock," New Eng. J. Med., 324:486-488 (1991).
D. C. Morrison, "Bacterial Endotoxins and Pathogenesis," Rev. Infect. Dis., 5(Supp 4):S733-S747 (1983).
R. C. Bone, "The Pathogenesis of Sepsis," Ann. Intern. Med., 115:457-469 (1991).
K. J. Tracey et al., "Shock and Tissue Injury Induced by Recombinant Human Cachectin," Science 234:470-474 (1986).
A. Tewari et al., "Preliminary Report: Effects of Interleukin-1 on Platelet Counts," Lancet 336:712-714 (1990).
J. B erdy, "Recent Developments of Antibiotic Research and Classification of Antibiotics According to Chemical Structure," in Advances in Applied Microbiology, (D. Perlman, ed.), Academic Press, New York, 18:309-406 (1974).
D. G. Maki, "Nosocomial Bacteremia: An Epidemiologic Overview," Am. J. Med., 70:719-732 (1981).
J. L. Shenep and K. A. Morgan, "Kinetics of Endotoxin Release During Antibiotic Therapy for Experimental Gram-Negative Bacterial Sepsis, " J. Inf. Dis., 150:380-388 (1984).
D. C. Morrison and D. M. Jacobs, "Binding of Polymyxin B to the Lipid A Portion of Bacterial Lipopolysaccharides," Immunochem., 13:813-818 (1976).
D. Rifkind and J. D. Palmer, "Neutralization of Endotoxin Toxicity in Chick Embryos by Antibiotics," J. Bact., 92:815-819 (1966).
D. C. Morrison and D. M. Jacobs, "Inhibition of Lipopolysaccharide-Initiated Activation of Serum Complement by Polmyxin B," Infect. Immun., 13:298-301 (1976).
M. S. Cooperstock, "Inactivation of Endotoxin B," Antimicrob. Agents Chemother., 6:422-425 (1974).
Physicians' Desk Reference, 47th Ed., pp. 818-819 (1993).
P. E. Hallaway et al., "Modulation of Deferoxamine Toxicity and Clearance by Covalent Attachment to Biocompatible Polymers," Proc. Natl. Acad. Sci. USA 86:10108-10112 (1989).
M. J. Poznansky and L. G. Cleland, "Biological Macromolecules as Carriers of Drugs and Enzymes," in Drug Delivery Systems: Characteristics and Biomedical Applications, (R. L. Juliano ed.), Oxford University Press, New York, pp. 253-315 (1980).
L. Molteni, "Dextrans as Drug Carriers," in Drug Carriers in Biology and Medicine, (G. Gregoriadis, ed.) Academic Press, New York, pp. 107-125 (1979).
C. Larsen, "Dextran Prodrugs-Structure and Stability in Relation to Therapeutic Activity," Adv. Drug Delivery Rev., 3:103-154 (1989).
A. D. Virnik et al., "Dextran and Its Derivatives," Russian Chem. Rev., 44:588-602 (1975).
G. Brownlee et al., "The Chemotherapy and Pharmacology of The Polymyxins," Brit. J. Pharmacol., 7:170-188 (1952).
Reynolds et al., in Martindale--The Extra Pharmacopoeia, 30th Ed., The Pharmaceutical Press, London, pp. 650-652 (1993).
W. A. Gibby et al., "Biodistribution and Magnetic Resonance Imaging of Cross-Linked DTPA Polysaccharides," Invest. Radio., 25:164-172 (1990).
J. J. Corrigan, Jr. and B. M. Bell, "Endotoxin-Induced Intravascular Coagulation: Prevention with Polymyxin B Sulfate," J. Lab. Clin. Med., 77:802-810 (1971).
B. Hughes et al., "Polymyxin B Sulphate Protects Cats Against the Haemodynamic and Metabolic Effects of E. coli Endotoxin," Br. J. Pharmac., 74:701-707 (1981).
J. J. Corrigan, Jr. and J. F. Kiernat, "Effect of Polymyxin B Sulfate on Endotoxin Activity in a Gram-Negative Septicemia Model," Pediat. Res., 13:48-51 (1979).
G. Ziv and W. D. Schultze, "Influence of Intrammary Infusion of Polymyxin B on the Clinicopathologic Course of Endotoxin-Induced Mastitis," Am. J. Vet. Res., 44:1446-1450 (1982).
G. Baldwin et al. "Effect of Polymyxin B on Experimental Shock from Meningococcal and Escherichia coli Endotoxins," J. Infect. Dis., 164:542-549 (1991).
A. H. L. From et al., "Polymyxin B Sulfate Modification of Bacterial Endotoxin: Effects on the Development of Endotoxin Shock in Dogs,"Infect. Immun., 23:660-664 (1979).
C. J. Ingoldby et al., "Endotoxemia in Human Obstructive Jaundice: Effect of Polymyxin B," Am. J. Surgery 147:766-771 (1984).
C. J. H. Ingoldby, "The Value of Polymixin B in Endotoxaemia Due to Experimental Obstructive Jaundice and Mesenteric Ischaemia," Br. J. Surg., 67:565-567 (1980).
J. W. Walterspiel et al., "Protective Effect of Subinhibitory Polymyxin B Alone and in Combination with Ampicillin for Overwhelming Haemophilus influenzae Type B Infection in the Infant Rat: Evidence for in Vivo and in Vitro Release of Free Endotoxin after Ampicillin Treatment," Pediat. Res., 20:237-241 (1986).
A. M. Munster et al., "Control of Endotoxemia in Burn Patients by Use of Polymyxin B," J. Burn Care Rehab., 10:327-330 (1989).
J. D. Baumgartner and M. P. Glauser, "Controversies in the Use of Passive Immunotherapy for Bacterial Infections in the Critically Ill Patient," Rev. Infect. Dis., 9:194-205 (1987).
E. J. Ziegler, "Protective Antibody to Endotoxin Core: The Emperor's New Clothes?," J. Infect. Dis., 158:286-290 (1988).
W. R. McCabe et al., "Type-Specific and Cross-Reactive Antibodies in Gram-Negative Bacteremia," New Eng. J. Med., 287:261-267 (1972).
A. I. Braude et al., "Antibody to Cell Wall Glycolipid of Gram-Negative Bacteria: Induction of Immunity of Bacteremia and Endotoxemia,"J. Infect. Dis., 136(Supp):S167-S173 (1977).
J. E. Pennington and E. Menkes, "Type-Specific vs. Cross-Protective Vaccination for Gram-Negative Bacterial Pneumonia," J. Infect. Dis., 144:599-603 (1981).
E. J. Ziegler et al., "Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant Escherichia coli," New. Eng. J. Med., 307:1225-1230 (1982).
W. R. McCabe et al., "Immunization with Rough Mutants of Salmonella minnesota: Protective Activity of IgM and IgG Antibody to the R595 (Re Chemotype) Mutant," J. Infect. Dis., 158:291-300 (1988).
D. L. Dunn et al., "Anticore Endotoxin F(ab').sub.2 Equine Immunoglobulin Fragments Protect Against Lethal Effects of Gram-Negative Bacterial Sepsis," Surgery 96:440-446 (1984).
S. J. Spier et al., "Protection Against Clinical Endotoxemia in Horses by Using Plasma Containing Antibody to an Rc Mutant E. coli (J5)," Circulatory Shock 28:235-248 (1989).
N. N. H. Teng et al., "Protection Against Gram-Negative Bacteremia and Endotoxemia with Human Monoclonal IgM Antibodies," Proc. Natl. Acad. Sci. USA 82:1790-1794 (1985).
E. J. Ziegler et al., "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody Against Endotoxin,"New. Eng. J. Med., 324:429-436 (1991).
R. L. Greenman et al., "A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis," JAMA 266:1097-1102 (1991).
K. A. Schulman et al., "Cost-Effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis: Economic Assessment of a New Therapeutic Agent," JAMA 266:3466-3471 (1991).
K. Ohlsson et al., "Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock," Nature 348:550-552 (1990).
S. M. Opal et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with Pseudomonas Aeruginosa," J. Infect. Dis., 161:1148-1152 (1990).
J.-D. Baumgartner et al., "Prevention of Gram-Negative Shock and Death in Surgical Patients by Antibody to Endotoxin Core Glycolipid,"Lancet 2:59-63 (1985).
T. C
Carroll Sean B.
Firca Joseph R.
Padhye Nisha V.
Pugh Charles
Chan Christina Y.
Eisenschenk Frank C.
Ophidian Pharmaceuticals Inc.
LandOfFree
Conjugates for the prevention and treatment of sepsis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates for the prevention and treatment of sepsis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates for the prevention and treatment of sepsis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1048650